


North Carolina Medicaid Special Bulletin



An Information Service of the
Division of Medical Assistance

Visit DMA on the Web at <http://www.ncdhhs.gov/dma>

Feb. 23, 2018

**Attention:
All Providers**

Correction Flovent HFA Inhaler Moved to Preferred Status on the Preferred Drug List

*Providers are responsible for informing their billing agency of information in this bulletin.
CPT codes, descriptors and other data only are copyright 2016 American Medical Association
All rights reserved. Applicable FARS/DFARS apply.*

The Special Medicaid Bulletin, *Generic Dispensing Rate Adjustments and Flovent HFA Inhaler Moved to Preferred Status on the Preferred Drug List*, had an incorrect date in the first sentence.

Here is the article with the correct information.

Effective Feb. 3, 2018, Flovent HFA Inhaler has been moved to preferred status on the North Carolina Medicaid and NC Health Choice (NCHC) Preferred Drug List (PDL). This change is being made since Teva Pharmaceuticals has discontinued sales of QVAR Inhaler and to allow providers another preferred inhaled corticosteroid option.

Teva is replacing QVAR Inhaler with QVAR RediHaler, which is non-preferred. Patients and caregivers are encouraged to speak with a healthcare professional about how this transition may impact their current treatment plan.

CORTICOSTEROIDS Clinical Criteria Apply	
Preferred	Non-Preferred
Pulmicort Respules 0.25mg, 0.5mg, 1mg	Aerospan Inhaler
QVAR Inhaler	Alvesco Inhaler
Flovent HFA Inhaler	Arnuity Elipta Inhaler
	Asmanex HFA Inhaler
	Asmanex Twisthaler
	budesonide suspension (generic for Pulmicort Respules)
	Flovent Diskus / HFA Inhaler
	Pulmicort Flexhaler
	QVAR RediHaler

Sandra Terrell, MS, RN
Director of Clinical
Division of Medical Assistance
Department of Health and Human Services

Paul Guthery
Executive Account Director
CSRA